Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.94 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.94 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.94 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartocin SCHEMBL29439933 | 1.00 | OXTR (0.94) | OXTRAVPR1AAVPR1BAVPR2 | |
| Aspartocin SCHEMBL193132 | 1.00 | OXTR (0.94) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL19712185 | 0.98 | OXTR (0.90) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL122621 | 0.98 | OXTR (0.90) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL29048 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL20707334 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL15512173 | 0.97 | OXTR (0.92) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL21527573 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL1173243 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL16373316 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066373-A1 | TREATING DIABETES WITH OXYTOCIN OR OXYTOCIN ANALOGS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-8211439-B2 | Albumin fusion proteins comprising insulin polypeptides | HUMAN GENOME SCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8012464-B2 | G-CSF-albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7799759-B2 | albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090099073-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093402-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080167240-A1 | comprising a wild-type erythropoietin polypeptide fused to wild-type albumin; albumin increases the serum plasma half-life of erythropoietin polypeptide; shelf life, storage stability; using nucleic acids, vectors, and/or host cells to treat anemia, bleeding disorder, chronic renal failure; gene therapy | HUMAN GENOME SCIENCES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167238-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167239-A1 | comprising a wild-type insulin polypeptide fused to wild-type albumin; albumin increases the serum plasma half-life of the insulin polypeptide; shelf life, storage stability; using nucleic acids, vectors, and/or host cells, for treating hyperglycemia, diabetes, hyperlipidemia; gene therapy | HUMAN GENOME SCIENCES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080161243-A1 | Chimeric B-type natriuretic peptide (BNP) polypeptide for use in treatment and prevention of cardiovascular disorders | HUMAN GENOME SCIENCES, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080153751-A1 | Chimeric colony stimulating factor for use in treatment and prevention of cell proliferative, blood, inflammatory and nervous system disorders | HUMAN GENOME SCIENCES, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080146503-A1 | albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146503-A1 | albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins | ALB, FABP1, HDGF | OXTR 3013/4885AVPR1A 3784/4885AVPR1B 4080/4885 |
| US-20090093402-A1 | Albumin Fusion Proteins | ALB, FABP1, HDGF | OXTR 3592/4885AVPR1A 3916/4885AVPR1B 4175/4885 |
| US-20090099073-A1 | Albumin Fusion Proteins | ALB, FABP1, HDGF | OXTR 3592/4885AVPR1A 3916/4885AVPR1B 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.